{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T13:31:49Z","timestamp":1788960709630,"version":"build-2803163510"},"reference-count":39,"publisher":"Wiley","issue":"12","license":[{"start":{"date-parts":[[2021,9,28]],"date-time":"2021-09-28T00:00:00Z","timestamp":1632787200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Journal of Viral Hepatitis"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>As pegylated interferon alpha (PEG\u2010IFN\u2010\u03b1) is increasingly used in combination regimens of novel drugs, we aimed to characterize ALT flares and their relationship with serum HBsAg and HBV RNA kinetics in a large combined cohort of chronic hepatitis B (CHB) patients on PEG\u2010IFN\u2010\u03b1\u2010based therapy. In this post hoc analysis of four international randomized trials, 269\/130\/124\/128 patients on PEG\u2010IFN\u2010\u03b1 monotherapy, PEG\u2010IFN\u2010\u03b1 plus nucleos(t)ide analogue (NA) de novo combination, PEG\u2010IFN\u2010\u03b1 add\u2010on to NA or NA monotherapy were included, respectively. A flare was defined as an episode of ALT \u22655\u00a0\u00d7\u00a0ULN. The association between flares and HBsAg and HBV RNA changes were examined. On\u2010treatment flares occurred in 83\/651 (13%) patients (median timing\/magnitude: week 8 [IQR 4\u201312], 7.6\u00a0\u00d7\u00a0ULN [IQR 6.2\u201310.5]). Flare patients were more often Caucasians with genotype A\/D and had higher baseline ALT, HBV DNA, HBV RNA and HBsAg levels than the no\u2010flare group. More flares were observed on PEG\u2010IFN\u2010\u03b1 monotherapy (18%) and PEG\u2010IFN+NA de novo combination (24%) vs. PEG\u2010IFN\u2010\u03b1 add\u2010on (2%) or NA monotherapy (1%) (<jats:italic>p<\/jats:italic>\u00a0&lt;\u00a0.001). On\u2010treatment flares were significantly and independently associated with HBsAg and HBV RNA decline \u22651\u00a0log<jats:sub>10<\/jats:sub> at the final visit declines started shortly before the flare, progressing towards 24\u00a0weeks thereafter. On\u2010treatment flares were seen in 16\/22 (73%) patients who achieved HBsAg loss. In conclusion, ALT flares during PEG\u2010IFN\u2010\u03b1 treatment are associated with subsequent HBsAg and HBV RNA decline and predict subsequent HBsAg loss. Flares rarely occurred during PEG\u2010IFN\u2010\u03b1 add\u2010on therapy and associated with low HBsAg loss rates. Combination regimens targeting the window of heightened response could be promising.<\/jats:p>","DOI":"10.1111\/jvh.13613","type":"journal-article","created":{"date-parts":[[2021,9,13]],"date-time":"2021-09-13T05:56:44Z","timestamp":1631512604000},"page":"1729-1737","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Effects of on\u2010treatment ALT flares on serum HBsAg and HBV RNA in patients with chronic HBV infection"],"prefix":"10.1111","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9119-4610","authenticated-orcid":false,"given":"Hannah S. J.","family":"Choi","sequence":"first","affiliation":[{"name":"Toronto Centre for Liver Disease University Health Network  Toronto ON Canada"},{"name":"Institute of Medical Science University of Toronto  Toronto ON Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9253-563X","authenticated-orcid":false,"given":"Milan J.","family":"Sonneveld","sequence":"additional","affiliation":[{"name":"Gastroenterology and Hepatology Erasmus University Medical Center  Rotterdam The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mina S.","family":"Farag","sequence":"additional","affiliation":[{"name":"Toronto Centre for Liver Disease University Health Network  Toronto ON Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8713-1481","authenticated-orcid":false,"given":"Willem P.","family":"Brouwer","sequence":"additional","affiliation":[{"name":"Gastroenterology and Hepatology Erasmus University Medical Center  Rotterdam The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7687-4036","authenticated-orcid":false,"given":"Sylvia M.","family":"Brakenhoff","sequence":"additional","affiliation":[{"name":"Gastroenterology and Hepatology Erasmus University Medical Center  Rotterdam The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grishma","family":"Hirode","sequence":"additional","affiliation":[{"name":"Toronto Centre for Liver Disease University Health Network  Toronto ON Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam J.","family":"Gehring","sequence":"additional","affiliation":[{"name":"Toronto Centre for Liver Disease University Health Network  Toronto ON Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rob A.","family":"de Man","sequence":"additional","affiliation":[{"name":"Gastroenterology and Hepatology Erasmus University Medical Center  Rotterdam The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bettina E.","family":"Hansen","sequence":"additional","affiliation":[{"name":"Toronto Centre for Liver Disease University Health Network  Toronto ON Canada"},{"name":"Institute of Health Policy, Management and Evaluation University of Toronto  Toronto ON Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harry L. A.","family":"Janssen","sequence":"additional","affiliation":[{"name":"Toronto Centre for Liver Disease University Health Network  Toronto ON Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2021,9,28]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep4.1281"},{"key":"e_1_2_9_3_1","volume-title":"A Study of the Oral Farnesoid X Receptor Modulator EYP001a to Assess Its Safety and Anti\u2010viral Effect in Chronic Hepatitis B Patients in Combination With Pegylated Interferon alpha2a Alone and With Entecavir","author":"Enyo Pharma","year":"2020"},{"key":"e_1_2_9_4_1","volume-title":"A Study of JNJ\u201073763989 + JNJ\u201056136379 + Nucleos(t)Ide Analog (NA) Regimen With or Without Pegylated Interferon Alpha\u20102a (PegIFN\u2010\u03b12a) in Treatment\u2010Naive Participants With Hepatitis B e Antigen (HBeAg) Positive Chronic Hepatitis B Virus (HBV) Infection and","author":"Janssen","year":"2020"},{"key":"e_1_2_9_5_1","volume-title":"Study of VIR\u20102218 With or Without Pegylated Interferon Alpha\u20102a for Treatment of Chronic Hepatitis B Virus Infection","author":"Vir Biotechnology","year":"2020"},{"key":"e_1_2_9_6_1","volume-title":"A Phase II Study of Hepalatide in Subjects With HBeAg\u2010positive Chronic Hepatitis B","author":"Shanghai HEP Pharmaceutical Co. Ltd","year":"2020"},{"key":"e_1_2_9_7_1","volume-title":"A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Doses of RO7049389 in Healthy Volunteers and Chronic Hepatitis B Virus (HBV) Infected Participants","author":"Roche H\u2010L","year":"2020"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2019.11.003"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(19)30344-9"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2019-318981"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2015.03.006"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.14560"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2017.12.013"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2004.062208"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cis859"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2017.08.021"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)17701-0"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2010.186"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.27586"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jix024"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.12833"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.27381"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.24555"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199605303342202"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1053\/jhep.2003.50148"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2015.09.043"},{"key":"e_1_2_9_27_1","first-page":"127A","article-title":"Addition of peginterferon alfa\u20102a increases HBsAg decline in HBeAg\u2010negative chronic hepatitis B patients treated with long\u2010term nucleos(t)ide analogue therapy: results from a multicenter randomized controlled trial (PAS Study)","volume":"70","author":"Farag MS","year":"2019","journal-title":"Hepatology"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1053\/jhep.2001.28459"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2013.01.026"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jir282"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.13449"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2019.02.005"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.1053\/jhep.2000.16333"},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.1136\/gut.51.4.597"},{"key":"e_1_2_9_35_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29640"},{"key":"e_1_2_9_36_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.306.6870.107"},{"key":"e_1_2_9_37_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2020.02.058"},{"key":"e_1_2_9_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(17)30288-1"},{"key":"e_1_2_9_39_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0156667"},{"key":"e_1_2_9_40_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2019.03.044"}],"container-title":["Journal of Viral Hepatitis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jvh.13613","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/jvh.13613","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jvh.13613","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,28]],"date-time":"2023-08-28T08:36:00Z","timestamp":1693211760000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jvh.13613"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,28]]},"references-count":39,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["10.1111\/jvh.13613"],"URL":"https:\/\/doi.org\/10.1111\/jvh.13613","archive":["Portico"],"relation":{},"ISSN":["1352-0504","1365-2893"],"issn-type":[{"value":"1352-0504","type":"print"},{"value":"1365-2893","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,28]]},"assertion":[{"value":"2021-02-15","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-08-27","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-09-28","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}